Pàgina inicial > Resultats de la cerca: Cho, B.C.
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 2 registres trobats en 0.01 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
12 p, 339.3 KB Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC : Results From the Phase 3 TAHOE Study / Blackhall, Fiona (Department of Medical Oncology. The Christie National Health Service (NHS) Foundation Trust) ; Jao, K. (Department of Hematology and Oncology. Hopital du Sacre Coeur Montreal) ; Greillier, L. (Multidisciplinary Oncology and Therapeutic Innovations Department. Centre de Recherche en Cancérologie de Marseille (CRCM). Centre National de la Recherche Scientifique (CNRS). Institut National de la Santé et de la Recherche Médicale (INSERM). Assistance Publique-Hopitaux de Marseille (APHM). Aix-Marseille University) ; Cho, B.C. (Division of Medical Oncology. Department of Internal Medicine. Yonsei Cancer Center. Yonsei University College of Medicine) ; Penkov, K. (Private Medical Institution Euromedservice) ; Reguart, Noemi (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Nackaerts, K. (Department of Pulmonology and Respiratory Oncology. University Hospital Leuven. Katholieke Universiteit (KU) Leuven) ; Syrigos, K. (Department of Medicine. National and Kapodistrian University of Athens) ; Hansen, K. (Odense University Hospital (Dinamarca)) ; Schuette, W. (2nd Medical Department. Krankenhaus Martha-Maria Halle-Doelau. Halle) ; Cetnar, J. (Department of Medicine. Oregon Health & Science University) ; Cappuzzo, F. (Department of Medical Oncology. Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)) ; Okamoto, I. (Department of Medical Oncology. Kyushu University Hospital) ; Erman, M. (Department of Medical Oncology. Cancer Institute. Hacettepe University) ; Langer, S.W. (Rigshospitalet. University of Copenhagen) ; Kato, T. (Department of Thoracic Oncology. Kanagawa Cancer Center) ; Groen, H. (Department of Pulmonary Disease. University Medical Center Groningen. University of Groningen) ; Sun, Z. (AbbVie. Inc.) ; Luo, Y. (AbbVie. Inc.) ; Tanwani, P. (AbbVie. Inc.) ; Caffrey, L. (AbbVie. Inc.) ; Komarnitsky, P. (AbbVie. Inc.) ; Reinmuth, N. (Thoracic Oncology Department. Asklepios Fachkliniken München-Gauting)
Introduction: DLL3, an atypical Notch ligand, is expressed in SCLC tumors but is not detectable in normal adult tissues. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate containing a DLL3-targeting antibody tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. [...]
2021 - 10.1016/j.jtho.2021.02.009
Journal of Thoracic Oncology, Vol. 16 Núm. 9 (september 2021) , p. 1547-1558  
Registre complet - Creative Commons
2.
15 p, 598.6 KB Five Year Survival Update From KEYNOTE-010 : Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC / Herbst, Roy S (Section of Medical Oncology. Yale Comprehensive Cancer Center. Yale University School of Medicine) ; Garon, E.B. (David Geffen School of Medicine. University of California Los Angeles) ; Kim, D.W. (Seoul National University Hospital. Seoul National University College of Medicine) ; Cho, B.C. (Yonsei Cancer Center. Yonsei University College of Medicine) ; Gervais, R. (Centre François Baclesse (Caen, França)) ; Perez-Gracia, J.L. (Clínica Universidad de Navarra) ; Han, J.Y. (Center for Lung Cancer. National Cancer Center) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Forster, M.D. (UCL Cancer Institute/University College London Hospitals) ; Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ; Novello, Silvia (Department of Oncology. University of Turin. Azienda Ospedaliero Universitaria San Luigi) ; Gubens, M.A. (University of California. San Francisco) ; Boyer, M. (Chris O'Brien Lifehouse) ; Su, W.C. (National Cheng Kung University Hospital) ; Samkari, A. (Merck & Co.. Inc.) ; Jensen, E.H. (Merck & Co.. Inc.) ; Kobie, J. (Merck & Co.. Inc.) ; Piperdi, B. (Merck & Co.. Inc.) ; Baas, Pieter (The Netherlands Cancer Institute (Amsterdam, Països Baixos))
Introduction: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. [...]
2021 - 10.1016/j.jtho.2021.05.001
Journal of Thoracic Oncology, Vol. 16 Núm. 10 (october 2021) , p. 1718-1732  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
1 Cho, BeLong
1 Cho, Byung-Sik
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem